These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
694 related articles for article (PubMed ID: 25304988)
1. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Sun Z; Wang Z; Liu X; Wang D Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988 [TBL] [Abstract][Full Text] [Related]
2. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Fumarola C; Bonelli MA; Petronini PG; Alfieri RR Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259 [TBL] [Abstract][Full Text] [Related]
3. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Gadgeel SM; Wozniak A Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287 [TBL] [Abstract][Full Text] [Related]
4. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. Papadimitrakopoulou V J Thorac Oncol; 2012 Aug; 7(8):1315-26. PubMed ID: 22648207 [TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine? Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635 [TBL] [Abstract][Full Text] [Related]
6. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Beck JT; Ismail A; Tolomeo C Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117 [TBL] [Abstract][Full Text] [Related]
7. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Polivka J; Janku F Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727 [TBL] [Abstract][Full Text] [Related]
9. Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer. Cuffe S; Leighl NB J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1805-7. PubMed ID: 22005538 [No Abstract] [Full Text] [Related]
11. The PI3K/AKT Pathway as a Target for Cancer Treatment. Mayer IA; Arteaga CL Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415 [TBL] [Abstract][Full Text] [Related]
12. A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells. Lee H; Kim SJ; Jung KH; Son MK; Yan HH; Hong S; Hong SS Oncol Rep; 2013 Aug; 30(2):863-9. PubMed ID: 23708425 [TBL] [Abstract][Full Text] [Related]
13. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Tan AC Thorac Cancer; 2020 Mar; 11(3):511-518. PubMed ID: 31989769 [TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds. Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575 [TBL] [Abstract][Full Text] [Related]
15. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231 [TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Zhou Q; Lui VW; Yeo W Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728 [TBL] [Abstract][Full Text] [Related]
17. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052 [TBL] [Abstract][Full Text] [Related]
18. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway. Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281 [TBL] [Abstract][Full Text] [Related]
19. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro. Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660 [TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]